Back to today’s briefing

Story perspectives

New Vaccine Platform Promises Healthier Future by 2029

5/6/2025

50 12

Summary

Story summary

The U.S. Department of Health and Human Services and NIH have unveiled the innovative "Generation Gold Standard" vaccine platform, harnessing beta-propiolactone to develop versatile vaccines targeting influenza and coronaviruses. This ambitious initiative prioritizes transparency and readiness, with clinical trials set to commence in 2026 and FDA approval anticipated by 2029, promising a healthier future.

1 of 1

Story summary

The U.S. Department of Health and Human Services and NIH have unveiled the innovative "Generation Gold Standard" vaccine platform, harnessing beta-propiolactone to develop versatile vaccines targeting influenza and coronaviruses. This ambitious initiative prioritizes transparency and readiness, with clinical trials set to commence in 2026 and FDA approval anticipated by 2029, promising a healthier future.